MCID: FLR002
MIFTS: 55

Filariasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 74 58 54 43 15 71 32
Disease Due to Superfamily Filarioidea 12

Characteristics:

Orphanet epidemiological data:

58
filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 34 125.9
MeSH 43 D005368
NCIt 49 C34611
SNOMED-CT 67 50342004
MESH via Orphanet 44 D005368
ICD10 via Orphanet 33 B74.0 B74.1 B74.2 more
UMLS via Orphanet 72 C0016085
Orphanet 58 ORPHA2034
UMLS 71 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and elephantiasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Diethylcarbamazine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and breast, and related phenotypes are immune system and hematopoietic system

Wikipedia : 74 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 710, show less)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 34.8 TLR4 TLR2 IL5 IL10
2 elephantiasis 33.7 IL5 IL10 FLT4
3 onchocerciasis 32.6 LGALS3BP IL5 IL2 IGHE CCL5
4 lymphadenitis 31.2 TNF TLR4 IL10 IFNG
5 hypereosinophilic syndrome 31.2 IL5 IL2 IL10 IGHE IFNG CCL5
6 ascaris lumbricoides infection 31.1 IL6 IL5 IFNG
7 endomyocardial fibrosis 31.0 TNF IL5 IL10
8 orchitis 31.0 TNF IL6 IL2 IL10
9 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IL10 IFNG CTLA4
10 encephalitis 30.9 TNF IL6 IL10 CCL5
11 yellow fever 30.8 IL6 IL5 CCL5
12 dengue disease 30.8 TNF CCL5 ALB
13 strongyloidiasis 30.7 LGALS3BP IL5 IGHE IFNG
14 trachoma 30.6 TNF IL6 IL10
15 cellulitis 30.6 TNF IL6 IL5 IL10 FLT4
16 lymphangiosarcoma 30.6 TNF FLT4
17 chikungunya 30.6 TNF IL6 CCL5
18 poliomyelitis 30.6 TNF IL10 IFNG
19 severe combined immunodeficiency 30.5 IL6 IL5 IL2 IL10 IFNG
20 taeniasis 30.4 TLR4 IL10 ALB
21 b cell deficiency 30.4 IL2 IL10 CTLA4
22 trichomoniasis 30.4 TNF IL6 IL2
23 ige responsiveness, atopic 30.4 IL5 IL10 IGHE IFNG
24 urinary schistosomiasis 30.4 IL5 IGHE IFNG CTLA4
25 panuveitis 30.4 TNF IL6 IL10
26 urticaria 30.4 TNF IL6 IL5 IGHE
27 pericarditis 30.3 TNF IL6 IFNG ALB
28 fascioliasis 30.3 IL10 IFNG ALB
29 amebiasis 30.3 TNF TLR4 TLR2 ALB
30 rheumatic heart disease 30.3 TNF TLR2 IL6 IL10
31 mastitis 30.3 TLR2 IL6 CCL5 ALB
32 protein-energy malnutrition 30.3 TNF IL6 ALB
33 cysticercosis 30.2 TLR4 PDCD1LG2 IL6 IL10 IGHE
34 schistosomiasis 30.2 TNF IL5 IL2 IL10 IGHE IFNG
35 typhoid fever 30.2 TNF TLR4 IL6 IFNG ALB
36 pleurisy 30.1 TNF TLR4 TLR2 IL2 IFNG
37 lepromatous leprosy 30.1 TNF TLR2 IL2 IL10 IFNG
38 bacterial infectious disease 30.1 TNF TLR9 TLR4 TLR2 TLR1 IL6
39 endocarditis 30.1 TNF TLR6 TLR2 IL6 IL10 IFNG
40 uveitis 30.1 TNF IL6 IL2 IL10 IFNG CTLA4
41 parasitic helminthiasis infectious disease 30.1 TNF TLR9 TLR4 TLR2 IL6 IL5
42 mucocutaneous leishmaniasis 30.1 TNF TLR9 IL2 IL10 IFNG
43 posterior uveitis 30.0 TNF IL6 IL5 IL2 IFNG
44 lichen planus 30.0 TNF IL6 IL2 IL10 IFNG
45 plasmodium falciparum malaria 30.0 TNF IL6 IL10 IFNG CHIT1
46 varicose veins 30.0 TNF LGALS3BP IL6 FOXC2
47 gastritis 30.0 TNF TLR4 IL6 IL10 CCL5
48 keratitis, hereditary 29.9 TNF TLR9 TLR4 TLR2 IL6 IL10
49 dengue hemorrhagic fever 29.9 TNF IL6 IL10 IFNG ALB
50 meningoencephalitis 29.9 TNF IL6 IL10 CCL5 ALB
51 exanthem 29.9 TNF IL6 IL2 IL10 CTLA4 ALB
52 tetanus 29.9 TNF IL6 IL5 IL2 IL10 IFNG
53 end stage renal failure 29.8 TNF IL6 IL2 CCL5 ALB
54 echinococcosis 29.8 TNF TLR4 TLR2 IL6 IL5 IL10
55 cystic echinococcosis 29.8 TLR4 TLR2 IL6 IL10 IGHE IFNG
56 leishmaniasis 29.8 TNF TLR9 TLR4 TLR2 IL6 IL5
57 acquired immunodeficiency syndrome 29.8 TNF IL6 IL2 IL10 IFNG ALB
58 plague 29.7 TNF TLR9 TLR6 TLR4 TLR2 IL6
59 visceral leishmaniasis 29.7 TNF TLR9 TLR4 TLR2 IL2 IL10
60 pulmonary tuberculosis 29.7 TNF TLR4 TLR2 IL6 IL2 IL10
61 diarrhea 29.7 TNF TLR4 IL6 IL5 IL2 IL10
62 immune deficiency disease 29.7 TNF IL6 IL2 IL10 IFNG CCL5
63 mycobacterium tuberculosis 1 29.7 TNF TLR9 TLR4 TLR2 TLR1 IL10
64 hepatitis b 29.6 TNF TLR4 TLR2 IL6 IFNG CTLA4
65 vascular disease 29.6 TNF TLR4 IL6 IL2 IL10 IFNG
66 leprosy 3 29.5 TNF TLR9 TLR6 TLR4 TLR2 TLR1
67 skin disease 29.5 TNF TLR4 TLR2 IL6 IL5 IL2
68 arthritis 29.5 TNF TLR4 TLR2 IL6 IL10 IFNG
69 keratoconjunctivitis 29.5 TNF IL6 IL5 IL2 IFNG CCL5
70 trypanosomiasis 29.4 TNF TLR9 TLR6 TLR4 TLR2 IL6
71 bronchitis 29.4 TNF TLR4 TLR2 IL6 IL5 IL10
72 allergic hypersensitivity disease 29.3 TNF TLR9 TLR4 TLR2 IL5 IL2
73 peritonitis 29.3 TNF TLR4 TLR2 IL6 IL10 IFNG
74 toxoplasmosis 29.3 TNF TLR9 TLR4 TLR2 TLR1 IL6
75 cutaneous leishmaniasis 29.2 TNF TLR9 TLR4 TLR2 IL6 IL5
76 autoimmune disease 29.2 TNF TLR9 IL6 IL5 IL2 IL10
77 lung disease 29.1 TNF TLR9 TLR4 TLR2 IL6 IL5
78 chagas disease 29.1 TNF TLR9 TLR6 TLR4 TLR2 IL6
79 malaria 29.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
80 psoriasis 29.0 TNF TLR9 TLR2 IL6 IL5 IL2
81 proteasome-associated autoinflammatory syndrome 1 28.9 TNF TLR6 TLR4 TLR2 IL6 IL5
82 dermatitis 28.9 TNF TLR9 TLR4 TLR2 IL6 IL5
83 parasitic protozoa infectious disease 28.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
84 systemic lupus erythematosus 28.5 TNF TLR9 TLR4 TLR2 IL6 IL5
85 asthma 27.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
86 dermatitis, atopic 27.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
87 loiasis 12.3
88 dirofilariasis 11.8
89 mansonelliasis 11.7
90 podoconiosis 11.5
91 dipetalonemiasis 11.5
92 setariasis 11.2
93 hydrocele 10.9
94 lymphedema 10.8
95 volvulus of midgut 10.7
96 punctate inner choroidopathy 10.7 TNF IL10
97 aztreonam allergy 10.6 IL5 IL2
98 tropical endomyocardial fibrosis 10.6 TNF IL10
99 external pathological resorption 10.6 TNF IL6
100 silo filler's disease 10.6 TLR4 TLR2 IL5
101 multifocal choroiditis 10.6 TNF IL10
102 lymphangitis 10.6
103 eosinophilic fasciitis 10.6 IL5 IFNG
104 microscopic polyangiitis 10.6 TNF CTLA4
105 spondylarthropathy 10.6 TNF TLR4 TLR2
106 prosthetic joint infection 10.6 TLR4 TLR2 IL6
107 inflammatory bowel disease 18 10.6 IL2 IL10 CTLA4
108 toxic pneumonitis 10.6 TLR6 TLR4
109 palladium allergic contact dermatitis 10.6 TNF IL10
110 acute transverse myelitis 10.6 IL6 IL10
111 myelitis 10.6 TNF IL6 IL10
112 fungal keratitis 10.6 TLR4 TLR2
113 alveolar echinococcosis 10.6 TNF TLR4 TLR2
114 cow milk allergy 10.6 TNF IL5 IL10
115 idiopathic anterior uveitis 10.6 TNF IL6
116 acute pericementitis 10.6 TLR6 TLR2
117 meningococcal meningitis 10.6 TLR9 TLR4 TLR2
118 spastic paraparesis 10.5 IL2 IL10 IFNG
119 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.5 IL2 IL10 CTLA4
120 schistosoma mansoni infection, susceptibility/ 10.5
121 cefaclor allergy 10.5 IL5 ALB
122 fixed drug eruption 10.5 IL2 IFNG
123 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 TNF IL6 IL5
124 bone sarcoma 10.5 IL6 IL10 CTLA4
125 nickel allergic contact dermatitis 10.5 IL5 IL10 IFNG
126 polyarticular juvenile idiopathic arthritis 10.5 TNF IFNG
127 streptococcal toxic-shock syndrome 10.5 TNF IL6 IL2
128 uremic pruritus 10.5 IL6 IL2
129 sympathetic ophthalmia 10.5 TNF IL10 CTLA4
130 nut allergy 10.5 IL5 IL10 IGHE
131 autoimmune myocarditis 10.5 TNF IFNG
132 mycobacterium abscessus 10.5 TNF TLR2 TLR1
133 post-transplant lymphoproliferative disease 10.5 TNF IL6 IL10
134 periapical periodontitis 10.5 TNF TLR2 IL6
135 haemophilus influenzae 10.5 TNF TLR2
136 dermatitis herpetiformis 10.5 TNF IL5 IL10
137 transverse myelitis 10.5 TNF IL6 IL10
138 pneumonic plague 10.5 TLR4 TLR2 IL2 IL10
139 bagassosis 10.5 TNF IL6 IL5
140 scleral disease 10.5 TNF IL6 IL2
141 tuberculoid leprosy 10.5 IL2 IL10 IFNG
142 eosinophilic pneumonia 10.5
143 pulmonary eosinophilia 10.5
144 egg allergy 10.5 IL5 IL10 IGHE
145 toxicodendron dermatitis 10.5 TNF IL2
146 respiratory syncytial virus infectious disease 10.5 IL5 CCL5
147 capillary disease 10.5 IL2 FLT4 ALB
148 erysipelas 10.5 TNF IL6 IL2
149 oral tuberculosis 10.5 TNF IL2 IFNG
150 burning mouth syndrome 10.5 TNF IL6 IL2
151 poems syndrome 10.5 TNF IL6 IL2
152 sporotrichosis 10.5 TNF IL10 IFNG
153 cardiac sarcoidosis 10.5 TNF IL5 IFNG
154 choroiditis 10.5 TNF IL10 IFNG
155 silicosis 10.5 TNF TLR4 IL10
156 macs syndrome 10.5 TNF IL10 IFNG
157 vulvovaginal candidiasis 10.5 TLR2 IL2 IFNG
158 scleritis 10.5 TNF IL5 IFNG
159 rosacea 10.5 TNF TLR2 IL6
160 lacrimal apparatus disease 10.5 TNF IL6 IL10
161 blau syndrome 10.5 TNF TLR4 TLR2 IL10
162 yemenite deaf-blind hypopigmentation syndrome 10.5
163 chronic graft versus host disease 10.5 IL10 IFNG ALB
164 central nervous system lymphoma 10.5 IL6 IL2 IL10
165 molluscum contagiosum 10.5 TNF TLR9 TLR2
166 cytomegalovirus retinitis 10.5 TNF IL10 IFNG
167 farmer's lung 10.5 TNF IL2 IGHE
168 churg-strauss syndrome 10.5 TNF IL5 IL2 IL10
169 cervicitis 10.5 TLR4 TLR2 IL6 IL2
170 corticosteroid allergy 10.5 IL5 IFNG ALB
171 pleural tuberculosis 10.5 TNF IL2 IFNG
172 intestinal perforation 10.5 IL6 CTLA4 ALB
173 crimean-congo hemorrhagic fever 10.5 TNF IL6 CHIT1
174 crohn's colitis 10.5 TNF IL2 IFNG
175 vogt-koyanagi-harada disease 10.5 TLR2 IL10 IFNG
176 leukemia, acute monocytic 10.5 TNF TLR4 IL6
177 b-cell growth factor 10.5 IL6 IFNG
178 hidradenitis 10.5 TNF TLR4 IFNG
179 hidradenitis suppurativa 10.5 TNF TLR4 IFNG
180 lymphoid interstitial pneumonia 10.5 TNF IL6 IL2
181 localized scleroderma 10.5 TNF IL6 IL2
182 obesity-hypoventilation syndrome 10.5 IL6 CCL5
183 capillary leak syndrome 10.5 IL6 IL2 ALB
184 mycetoma 10.5 IL10 CHIT1 CCL5
185 periapical granuloma 10.5 TLR2 IL2 CCL5
186 neonatal jaundice 10.5 TNF IL6 IL10
187 cryptococcosis 10.5 TNF IL10 IFNG
188 status asthmaticus 10.5 IL5 IL10 CCL5
189 necrotizing fasciitis 10.5 IL6 IL2 ALB
190 genital herpes 10.5 TLR2 IL10 CCL5
191 pneumonic tularemia 10.4 TNF TLR4 TLR2 IL6
192 tularemia 10.4 TNF TLR4 TLR2 IL6
193 pulmonary alveolar proteinosis 10.4 TNF IL6 IL10
194 cystitis 10.4 TNF TLR4 IL6 IL2
195 dental pulp disease 10.4 TNF TLR4 TLR2 IL6
196 toxic oil syndrome 10.4 IL5 IGHE IFNG
197 chronic beryllium disease 10.4 TNF IFNG
198 urethritis 10.4 TNF TLR4 TLR2 IL6
199 primary progressive multiple sclerosis 10.4 TNF IL10 CTLA4
200 hantavirus hemorrhagic fever with renal syndrome 10.4 TNF IL6 ALB
201 congenital lymphedema 10.4 FOXC2 FLT4
202 fallopian tube disease 10.4 TNF TLR4 TLR2 IL6
203 autoimmune disease of blood 10.4 IL6 IL2 IL10 CTLA4
204 acute pyelonephritis 10.4 IL6 IL10 ALB
205 aseptic meningitis 10.4 TNF IL10 IFNG
206 hypersensitivity reaction type iii disease 10.4 TNF IL6 ALB
207 gastrointestinal tuberculosis 10.4 TNF IFNG ALB
208 neurosyphilis 10.4 TLR6 TLR2 TLR1 IL10
209 intestinal tuberculosis 10.4 TNF IFNG ALB
210 decubitus ulcer 10.4 TNF IL6 ALB
211 endometritis 10.4 TNF TLR4 TLR2 IL6
212 sebaceous gland disease 10.4 TNF TLR4 TLR2 IL6
213 macular retinal edema 10.4 TNF IL6 ALB
214 myd88 deficiency 10.4 TLR6 TLR4 TLR2 TLR1
215 abdominal tuberculosis 10.4 TNF IFNG ALB
216 irak4 deficiency 10.4 TLR6 TLR4 TLR2 TLR1
217 pneumocystosis 10.4 TNF IL6 ALB
218 scorpion envenomation 10.4 TNF IL6 CCL5
219 neurofibromatosis, type ii 10.4 TNF TLR2 IL6
220 compartment syndrome 10.4 TNF IL6 ALB
221 inflammatory bowel disease 1 10.4 TNF TLR4 TLR2 IL6
222 cecal disease 10.4 TNF IL6 ALB
223 hypersplenism 10.4 TLR4 IFNG ALB
224 preterm premature rupture of the membranes 10.4 TNF TLR4 TLR2 IL6
225 combined t cell and b cell immunodeficiency 10.4 IL6 IL2 IL10 CTLA4
226 epstein-barr virus-associated gastric carcinoma 10.4 TNF PDCD1LG2 IL10
227 drug allergy 10.4 IL5 IGHE ALB
228 chronic active epstein-barr virus infection 10.4 IL2 IL10 IFNG CTLA4
229 miliary tuberculosis 10.4 TNF IFNG ALB
230 staphylococcal toxic shock syndrome 10.4 TNF IGHE IFNG
231 meconium aspiration syndrome 10.4 TNF IL6 IFNG
232 legionellosis 10.4 TNF TLR4 TLR2 IL6
233 chronic ulcer of skin 10.4 TNF IL6 ALB
234 ocular toxoplasmosis 10.4 TLR9 TLR1 IGHE
235 purpura 10.4 TNF IL6 IL10
236 chronic eosinophilic pneumonia 10.4 IL6 IL5 CCL5
237 intermittent claudication 10.4 IL6 IL10 ALB
238 pneumoconiosis 10.4 TNF IL6 IL10
239 eosinophilic meningitis 10.4 IL5 IL2 IL10 IGHE
240 penicillin allergy 10.4 IL10 IGHE IFNG
241 niemann-pick disease 10.4 TLR4 IL6 IL10 CHIT1
242 exocrine pancreatic insufficiency 10.4 TNF IGHE CTLA4
243 pericardium disease 10.4 TNF IL6 ALB
244 neuromuscular junction disease 10.4 IL2 IL10 CTLA4 ALB
245 diverticulitis 10.4 TNF IL6 ALB
246 complex regional pain syndrome 10.4 TNF IL6 IL2 IL10
247 bacteriuria 10.4 TLR4 TLR2 TLR1 IL6
248 chorioamnionitis 10.4 TNF TLR4 IL6 IL10
249 duodenal ulcer 10.4 TNF TLR4 IL6 IL10
250 hepatic vascular disease 10.4 TNF IL6 ALB
251 apnea, obstructive sleep 10.4 TNF IL6 ALB
252 stachybotrys chartarum 10.4 TNF IL6 CCL5
253 prostatitis 10.4 TNF IL6 IL2 IL10
254 collagen disease 10.4 TNF IL6 IL10
255 anaerobic pneumonia 10.4 TLR6 IL6 CCL5
256 epidemic typhus 10.4 TLR4 TLR2 CCL5
257 coronary stenosis 10.4 TLR4 IL6 ALB
258 alopecia 10.4 TNF IL2 IFNG CTLA4
259 dengue shock syndrome 10.4 TNF IL6 ALB
260 acute graft versus host disease 10.4 TNF IL2 IL10 IFNG
261 paranasal sinus disease 10.4 TNF IL5 IL10 IFNG
262 prediabetes syndrome 10.4 TNF IL6 ALB
263 septic arthritis 10.4 TLR9 TLR4 TLR2 IFNG
264 shigellosis 10.4 TNF TLR4 IL10 ALB
265 cerebral palsy 10.4 TNF TLR4 IL6 IL10
266 fibromyalgia 10.4 TNF IL6 IL2 IL10
267 endocrine pancreas disease 10.4 TNF IL6 ALB
268 autoimmune pancreatitis 10.4 TNF IL10 CTLA4 ALB
269 vernal keratoconjunctivitis 10.4 IL5 IGHE CCL5
270 cytomegalovirus infection 10.4 TNF IL6 CCL5
271 infective endocarditis 10.4 TNF TLR6 TLR2 IL6
272 radiculopathy 10.4 IL6 IL10 CCL5
273 x-linked recessive disease 10.4 IL2 IL10 CTLA4 ALB
274 multicentric castleman disease 10.4 IL6 IL5 IL10 IFNG
275 castleman disease 10.4 IL6 IL5 IL10 IFNG
276 autoimmune uveitis 10.4 TNF IL2 IL10 IFNG
277 peptic ulcer disease 10.4 TNF IL10 ALB
278 autoimmune lymphoproliferative syndrome 10.4 TNF IL2 IL10 CTLA4
279 vein disease 10.4 TNF IL6 ALB
280 hand, foot and mouth disease 10.4 TLR4 IL6 IL10 IFNG
281 mouth disease 10.4 TLR4 IL6 IL10 IFNG
282 milk allergy 10.4 TNF IL5 IL10 IGHE
283 smallpox 10.4 TNF IL2 IFNG
284 relapsing polychondritis 10.4 IL6 IL2 IL10 IFNG
285 folliculitis 10.4 IL5 IFNG CCL5
286 kimura disease 10.4 IL5 IGHE CCL5
287 hansen's disease 10.4
288 endophthalmitis 10.4 TNF TLR2 IL6 ALB
289 primary lymphedema 10.4 FOXC2 FLT4
290 atrophic gastritis 10.4 TNF IL6 IL10
291 fabry disease 10.4 TNF IL6 CHIT1
292 null-cell leukemia 10.4 TNF IL6
293 endocardium disease 10.4 TNF TLR2 IL6 ALB
294 hemophagocytic lymphohistiocytosis 10.4 TNF IL10 IFNG CTLA4
295 hepatitis e 10.4 TNF IFNG ALB
296 autoimmune hepatitis 10.4 TNF IL10 CTLA4 ALB
297 mycosis fungoides 10.4 IL5 IL2 IFNG CTLA4
298 eales disease 10.4 TNF IL6 IL10 IFNG
299 drug-induced lupus erythematosus 10.4 TNF IL6 IL10 ALB
300 kala-azar 1 10.4
301 fungal meningitis 10.4 TNF IL6 IL10 IFNG
302 skin sarcoidosis 10.4 TNF CTLA4
303 atopic keratoconjunctivitis 10.4 IL5 IL2 IGHE IFNG
304 microscopic colitis 10.4 TNF IL6 IL2 IFNG
305 central nervous system vasculitis 10.4 TNF IL6 IFNG CTLA4
306 lichen disease 10.4 TNF IL6 IL2 IFNG
307 cutaneous lupus erythematosus 10.3 TNF IL6 IL10 IFNG
308 cryoglobulinemia 10.3 TNF IL6 IL10 IFNG
309 peanut allergy 10.3 IL5 IL10 IGHE IFNG
310 mixed connective tissue disease 10.3 TNF IL6 IL10 IFNG
311 multidrug-resistant tuberculosis 10.3 TNF IL10 IFNG ALB
312 lens disease 10.3 TNF IL6 ALB
313 spondylitis 10.3 TNF IL6 IL10 IFNG
314 allergic bronchopulmonary aspergillosis 10.3 IL5 IL10 IGHE IFNG
315 intracranial berry aneurysm 10.3 TNF TLR4 IL6 ALB
316 thymoma 10.3 TNF IL6 IL2 CTLA4
317 gingival disease 10.3 TNF TLR4 TLR2 IL6 IL10
318 secondary progressive multiple sclerosis 10.3 IL10 IFNG ALB
319 fasciitis 10.3 TNF IL6 IL2 IFNG
320 blood coagulation disease 10.3 TNF IL6 IL2 ALB
321 ileus 10.3 TNF IL6 IL10 IFNG
322 hepatic encephalopathy 10.3 TNF IL6 ALB
323 sleep apnea 10.3 TNF IL6 IL10 ALB
324 aggressive periodontitis 10.3 TNF TLR4 TLR2 IL6 IL10
325 fatty liver disease 10.3 TNF TLR4 IL6 ALB
326 familial mediterranean fever 10.3 TNF TLR4 TLR2 IL6 IL10
327 kawasaki disease 10.3 TNF IL6 IL10 ALB
328 nervous system disease 10.3 TNF IL6 IFNG ALB
329 monocytic leukemia 10.3 TNF TLR4 IL6 IFNG
330 retinal vascular disease 10.3 TNF IL6 ALB
331 latex allergy 10.3 TNF IL5 IGHE IFNG
332 disseminated intravascular coagulation 10.3 TNF IL6 IL10
333 thyroiditis 10.3 TNF IL6 IL2 IL10 CTLA4
334 toxic encephalopathy 10.3 TNF IL6 ALB
335 scrub typhus 10.3 TNF TLR4 TLR2 IL10 IFNG
336 autoimmune disease of eyes, ear, nose and throat 10.3 TNF IL6 IL2 IL10 CTLA4
337 viral meningitis 10.3 IL6 IFNG CCL5
338 viral pneumonia 10.3 TNF IL6 IL10 CCL5
339 sezary's disease 10.3 IL5 IL2 IL10 IFNG CTLA4
340 bone resorption disease 10.3 TNF IL6 ALB
341 idiopathic nephrotic syndrome 10.3 IGHE ALB
342 herpes zoster 10.3 TNF TLR2 IL2 IL10 IFNG
343 exudative vitreoretinopathy 1 10.3 TNF IL6 ALB
344 viral encephalitis 10.3 TNF IL6 IL10 CCL5
345 lung abscess 10.3 TNF IL6 IFNG ALB
346 non-alcoholic steatohepatitis 10.3 TNF IL6
347 tuberculous peritonitis 10.3 IFNG ALB
348 orofacial granulomatosis 10.3 TNF IL10 IFNG CCL5
349 adult respiratory distress syndrome 10.3 TNF IL6 IL10
350 triiodothyronine receptor auxiliary protein 10.3
351 lymphangiectasis 10.3
352 combat disorder 10.3 TLR9 TLR6 TLR4 TLR2 TLR1
353 brain edema 10.3 IL6 IL2 IFNG ALB
354 inherited metabolic disorder 10.3 TNF IL6 CHIT1 ALB
355 atherosclerosis susceptibility 10.3 TNF TLR4 IL6 ALB
356 myositis 10.3 TNF IL6 IL2 IFNG
357 blood group, globoside system 10.3 TNF TLR4 TLR2 IL6 ALB
358 pyelitis 10.3 TNF TLR4 TLR2 IL6 ALB
359 pleural disease 10.3 TNF IL6 IFNG ALB
360 glomerulonephritis 10.3
361 ascaridiasis 10.3
362 myasthenia gravis 10.3 TNF IL2 IL10 IFNG CTLA4
363 bronchopneumonia 10.3 TNF TLR4 IL6 IL10 ALB
364 pulmonary sarcoidosis 10.3 TNF IL2 IFNG CCL5
365 mycoplasma pneumoniae pneumonia 10.3 TNF TLR2 IL6 IL10 IFNG
366 gout 10.3 TNF TLR4 TLR2 IL6 ALB
367 parenchymatous neurosyphilis 10.3 TLR6 TLR1
368 obstructive jaundice 10.3 TNF TLR4 IL6 IL2 ALB
369 spinal cord disease 10.3 TNF IL6 IL2 IL10 ALB
370 chorioretinitis 10.3 TNF IL6 IL2 IL10 IFNG
371 allergic contact dermatitis 10.3 TNF IL6 IL5 IL10 IFNG
372 hypotrichosis 1 10.3 TNF IL6 IL2 IL10 ALB
373 autoimmune disease of urogenital tract 10.3 TNF IL6 IL10 CTLA4 ALB
374 autoimmune gastritis 10.3 TNF IL6 IL2 IL10 IFNG
375 hydrocephalus 10.3 TNF TLR4 TLR2 IL10 IFNG
376 chronic inflammatory demyelinating polyradiculoneuropathy 10.3 IL10 IFNG CCL5 ALB
377 polyradiculoneuropathy 10.3 IL10 IFNG CCL5 ALB
378 intermediate uveitis 10.3 TNF IL6 IL2 IL10 IFNG
379 subacute sclerosing panencephalitis 10.3 TNF IL6 IL2 IL10 IFNG
380 vaccinia 10.3 TNF TLR6 IL6 IL2 CTLA4
381 coronary artery anomaly 10.3 TNF IL6 IL10 ALB
382 extrapulmonary tuberculosis 10.3 TNF TLR2 IL10 IFNG ALB
383 bone remodeling disease 10.3 TNF IL6 ALB
384 acute pancreatitis 10.3 TNF TLR4 IL6 IL10 ALB
385 plasmodium vivax malaria 10.2 TNF IL6 IL2 IL10 IFNG
386 graft-versus-host disease 10.2 TNF IL6 IL2 IL10 IFNG
387 lymphopenia 10.2 IL6 IL2 IL10 IFNG CTLA4
388 chronic conjunctivitis 10.2 TNF IL6 IL5 IL10 IGHE
389 overnutrition 10.2 TNF TLR4 IL6 IL10 ALB
390 mumps 10.2 TNF IL6 IL2 IL10 IFNG
391 blood platelet disease 10.2 TNF IL6 IL2 IL10 ALB
392 sickle cell anemia 10.2 TNF IL6 ALB
393 spondyloarthropathy 10.2 TNF IL6 IL2 IL10 IFNG
394 glucose metabolism disease 10.2 TNF TLR4 IL6 IL10 ALB
395 acquired metabolic disease 10.2 TNF TLR4 IL6 IL10 ALB
396 lipid storage disease 10.2 TNF TLR4 IL6 CHIT1 ALB
397 granulomatosis with polyangiitis 10.2 TNF TLR9 TLR4 TLR2 IL5 CTLA4
398 listeriosis 10.2 TNF TLR4 TLR2 IL6 IL2 IL10
399 diphtheria 10.2 TNF IL5 IL2 IFNG ALB
400 leptin deficiency or dysfunction 10.2 TNF IL6 ALB
401 japanese encephalitis 10.2
402 ancylostomiasis 10.2
403 chylothorax, congenital 10.2 FOXC2 FLT4
404 non-alcoholic fatty liver disease 10.2 TNF TLR4 IL6 IL10 ALB
405 idiopathic neutropenia 10.2 TNF TLR4 IL6 IL10 CCL5
406 clonorchiasis 10.2 TNF IL2 IL10 IGHE IFNG
407 esophagitis 10.2 TNF IL6 IL5 IL10 CCL5
408 hypotrichosis 10.2 TNF IL2 FOXC2 FLT4 ALB
409 omenn syndrome 10.2 TNF IL5 IL10 IGHE IFNG
410 takayasu arteritis 10.2 TNF IL6 IL2 IL10 CCL5
411 cytokine deficiency 10.2
412 pertussis 10.2 TNF TLR4 IL6 IL10 CCL5
413 bacterial vaginosis 10.2 TNF TLR9 TLR4 TLR2 IL6 IL10
414 penile disease 10.2 TNF TLR9 TLR4 TLR2 IL6 IL2
415 spotted fever 10.2 TNF IL10 IFNG CTLA4 CCL5
416 spotted fever rickettsiosis 10.2 TNF IL10 IFNG CTLA4 CCL5
417 autoimmune disease of cardiovascular system 10.2 TNF PDCD1LG2 IL6 IL2 CTLA4
418 irritable bowel syndrome 10.2 TNF TLR9 TLR4 TLR2 IL6 IL10
419 stevens-johnson syndrome/toxic epidermal necrolysis 10.2 TLR9 IL5 IL2 IFNG CCL5
420 superficial basal cell carcinoma 10.2 TLR9 TLR6 TLR4 TLR2 TLR1 IL2
421 anogenital venereal wart 10.2 TLR9 TLR6 TLR4 TLR2 TLR1 IL2
422 dysentery 10.2 TNF TLR4 TLR2 IL6 IL10 ALB
423 acute cystitis 10.2 TNF TLR4 TLR2 IL6 IL10 ALB
424 herpes simplex 10.2 TNF TLR9 TLR2 CCL5
425 alcoholic liver cirrhosis 10.2 TNF TLR4 TLR2 IL6 IL10 ALB
426 corneal disease 10.2 TNF TLR4 TLR2 IL6 IL10 ALB
427 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
428 splenomegaly 10.2
429 tropical spastic paraparesis 10.2 IL6 IL2 IL10 IFNG CCL5
430 reactive arthritis 10.2 TNF TLR4 TLR2 IL6 IL10 IFNG
431 kidney cancer 10.2 TNF IL2 IFNG FLT4 ALB
432 periodontitis 10.2 TNF TLR4 TLR2 IL6 IL10 IFNG
433 sclerosing cholangitis 10.2 TNF TLR4 IL6 IL2 IL10 ALB
434 pre-eclampsia 10.1 TNF TLR4 IL6 IL10 ALB
435 brucellosis 10.1 TNF TLR4 IL6 IL2 IL10 IFNG
436 pelvic inflammatory disease 10.1 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
437 african tick-bite fever 10.1 TNF IL6 IL10 IFNG CCL5
438 bronchiolitis obliterans 10.1 TNF TLR4 IL6 IL10 IFNG CTLA4
439 hair disease 10.1 TNF IL6 IL2 IL10 CTLA4 ALB
440 sarcoidosis 1 10.1 TNF IL2 IFNG CHIT1 CCL5
441 arteriosclerosis 10.1 TLR4 IL6 IL10 IFNG CCL5
442 autoimmune disease of endocrine system 10.1 TNF IL6 IL2 IL10 IFNG CTLA4
443 lymphoma, non-hodgkin, familial 10.1 TNF IL6 IL2 IL10 CTLA4
444 uveal disease 10.1 TNF IL6 IL2 IL10 IFNG CTLA4
445 neuritis 10.1 TNF IL6 IL10 IFNG CCL5
446 muscular disease 10.1 TNF TLR4 IL6 IL2 IL10 ALB
447 ulcerative colitis 10.1 TNF TLR4 IL6 IL2 IL10 IFNG
448 alopecia areata 10.1 TNF IL6 IL2 IL10 IFNG CTLA4
449 temporal arteritis 10.1 TNF IL6 IFNG CTLA4 CCL5
450 breast cancer 10.1
451 west nile virus 10.1
452 nephrotic syndrome 10.1
453 yellow nail syndrome 10.1 FOXC2 ALB
454 vaginitis 10.1 TNF TLR4 TLR2 IL6 IL10 CCL5
455 neuromuscular disease 10.1 TNF IL6 IL2 IL10 CTLA4 ALB
456 ileitis 10.1 TNF TLR4 TLR2 IL6 IL10 CCL5
457 central nervous system disease 10.1 TNF IL6 IFNG ALB
458 macular degeneration, age-related, 1 10.1 TNF TLR4 TLR2 IL6 FLT4 ALB
459 allergic conjunctivitis 10.1 TNF IL5 IL2 IL10 IGHE IFNG
460 allergic rhinitis 10.1 IL5 IL10 IGHE IFNG CCL5
461 lyme disease 10.1 TNF TLR9 TLR6 TLR2 TLR1 IL6
462 extrinsic allergic alveolitis 10.1 IL6 IL10 IGHE CCL5 ALB
463 fibrosis of extraocular muscles, congenital, 1 10.1
464 pulmonary hypertension 10.1
465 dracunculiasis 10.1
466 scabies 10.1
467 epididymo-orchitis 10.1
468 toxocariasis 10.1
469 48,xyyy 10.1
470 leukemia, chronic lymphocytic 10.1 TNF TLR9 IL6 IL2 IL10 CTLA4
471 stomatitis 10.1 TNF TLR4 TLR2 IL6 IL2 IL10
472 primary systemic mycosis 10.1 TNF TLR4 TLR2 IL6 IL2 IL10
473 toxic shock syndrome 10.0 TNF TLR4 TLR2 IL6 IL2 IL10
474 chlamydia pneumonia 10.0 TNF TLR6 TLR4 TLR2 TLR1 IL6
475 rubella 10.0 TNF TLR4 IL6 IL5 IL2 IL10
476 erythema multiforme 10.0 TNF IL6 IL5 IL2 IFNG CCL5
477 pancreatic adenocarcinoma 10.0 TNF IL6 IL2 IL10 ALB
478 cholangitis 10.0 TNF TLR4 IL6 IL2 IL10 CTLA4
479 leukocyte disease 10.0 TNF IL6 IL5 IL2 IL10 CTLA4
480 bacterial sepsis 10.0 TNF TLR9 TLR4 TLR2 TLR1 IL6
481 leukemia, acute myeloid 10.0 TNF IL6 IL2 IL10 CTLA4 ALB
482 severe acute respiratory syndrome 10.0 TNF IL6 IL2 IL10 IFNG CCL5
483 hashimoto thyroiditis 10.0 TNF IL6 IL5 IL2 IL10 IFNG
484 middle ear disease 10.0 TNF TLR9 TLR4 TLR2 IL6 IL10
485 chlamydia 10.0 TNF TLR9 TLR4 TLR2 IL6 IL10
486 human immunodeficiency virus infectious disease 10.0 TNF TLR9 IL2 IL10 IFNG CCL5
487 respiratory failure 10.0 TNF IL6 IL5 IL10 CCL5 ALB
488 cone-rod dystrophy 2 10.0 TNF IL6 IL2 CTLA4 ALB
489 bacterial pneumonia 10.0 TNF TLR9 TLR4 TLR2 IL6 IL10
490 alcoholic hepatitis 10.0 TNF TLR9 TLR4 TLR2 IL6 IL10
491 hepatitis a 10.0 TNF TLR4 IL2 IL10 IFNG CTLA4
492 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.0
493 hydrops, lactic acidosis, and sideroblastic anemia 10.0
494 sleeping sickness 10.0
495 keratomalacia 10.0
496 rift valley fever 10.0
497 coccidioidomycosis 10.0
498 lymphangioma 10.0
499 angioedema 10.0
500 lymphocele 10.0
501 t-cell leukemia 10.0
502 47,xyy 10.0
503 rare lymphatic malformation 10.0
504 invasive aspergillosis 10.0 TLR9 TLR6 TLR4 TLR2 TLR1 IL10
505 melioidosis 10.0 TNF TLR4 TLR2 TLR1 IL6 IL10
506 chronic mucocutaneous candidiasis 10.0 TNF TLR2 TLR1 IL6 IL5 IL10
507 human immunodeficiency virus type 1 10.0 TNF IL6 IL2 IL10 IFNG CCL5
508 leptospirosis 10.0 TNF TLR2 TLR1 IL6 IL2 IL10
509 myelodysplastic syndrome 10.0 TNF IL6 IL2 IL10 IFNG ALB
510 rheumatic fever 10.0 TNF TLR2 IL6 IL2 IL10 IFNG
511 appendicitis 10.0 TNF TLR4 IL6 IL2 IL10 IFNG
512 juvenile rheumatoid arthritis 10.0 TNF IL6 IL2 IL10 IFNG CTLA4
513 aphthous stomatitis 10.0 TNF TLR4 TLR2 IL6 IL5 IL2
514 contact dermatitis 9.9 TNF TLR4 TLR2 IL6 IL5 IL2
515 gastroenteritis 9.9 TNF TLR9 IL6 IL5 IL10 IFNG
516 osteomyelitis 9.9 TNF TLR4 TLR2 IL6 IL10 IFNG
517 chickenpox 9.9 TNF TLR9 IL6 IL2 IL10 IFNG
518 gingivitis 9.9 TNF TLR2 IL6 IL2 IL10 IFNG
519 psoriatic arthritis 9.9 TNF TLR4 TLR2 IL6 IL2 IL10
520 angiosarcoma 9.9
521 sparganosis 9.9
522 giardiasis 9.9
523 st. louis encephalitis 9.9
524 hemopericardium 9.9
525 pericardial effusion 9.9
526 goiter 9.9
527 leukemia 9.9
528 trichuriasis 9.9
529 rheumatic disease 9.9
530 keratosis 9.9
531 impotence 9.9
532 enthesopathy 9.9
533 arthropathy 9.9
534 immune-complex glomerulonephritis 9.9
535 inflammatory breast carcinoma 9.9
536 amyloidosis 9.9
537 trichinosis 9.9
538 chronic pain 9.9
539 anus disease 9.9 TNF TLR9 TLR4 TLR2 TLR1 IL6
540 relapsing-remitting multiple sclerosis 9.9 TNF TLR4 IL6 IL2 IL10 IFNG
541 candidiasis 9.9 TNF TLR4 TLR2 IL6 IL2 IL10
542 osteoporosis 9.9 TNF TLR4 IL6 IL2 IL10 IFNG
543 demyelinating disease 9.9 TNF IL6 IL2 IL10 IFNG CTLA4
544 perinatal necrotizing enterocolitis 9.9 TNF TLR9 TLR6 TLR4 TLR2 TLR1
545 endometrial disease 9.9 TNF TLR9 TLR6 TLR4 TLR2 TLR1
546 streptococcus pneumonia 9.9 TNF TLR9 TLR6 TLR4 TLR2 TLR1
547 lymph node disease 9.9 TNF TLR4 TLR2 IL6 IL2 IL10
548 pyelonephritis 9.9 TNF TLR4 IL6 IL10 IFNG CCL5
549 autoimmune disease of gastrointestinal tract 9.9 TNF TLR4 IL6 IL2 IL10 IFNG
550 interstitial lung disease 9.9 TNF IL6 IL5 IL10 IFNG CCL5
551 myocarditis 9.9 TNF TLR4 IL6 IL2 IL10 IFNG
552 common cold 9.9 TNF TLR4 TLR2 IL6 IL5 IL10
553 gingival overgrowth 9.8 TNF IL6 IL2
554 bacterial meningitis 9.8 TNF TLR9 TLR4 TLR2 IL6 IL10
555 pulmonary disease, chronic obstructive 9.8 TNF TLR4 TLR2 IL6 IL5 IL10
556 paracoccidioidomycosis 9.8 TNF TLR4 TLR2 IL6 IL5 IL2
557 respiratory allergy 9.8 TNF TLR4 TLR2 IL6 IL5 IL10
558 chronic fatigue syndrome 9.8 TNF TLR4 IL6 IL5 IL2 IL10
559 allergic asthma 9.8 TLR4 TLR2 IL5 IL10 IGHE IFNG
560 dilated cardiomyopathy 9.8 TNF TLR4 IL6 IL2 IL10 IFNG
561 esophageal cancer 9.8 TNF TLR4 PDCD1LG2 IL6 IL2 IL10
562 aplastic anemia 9.8 TNF TLR9 IL6 IL2 IL10 IFNG
563 extrinsic cardiomyopathy 9.8 TNF TLR9 TLR4 TLR2 TLR1 IL6
564 colitis 9.8 TNF TLR9 TLR4 TLR2 IL6 IL2
565 q fever 9.8 TNF TLR4 TLR2 TLR1 IL6 IL10
566 measles 9.8 TNF TLR9 TLR4 TLR2 IL6 IL2
567 common variable immunodeficiency 9.8 TNF TLR9 TLR2 IL6 IL5 IL2
568 bladder cancer 9.8
569 epidermoid cysts 9.8
570 melkersson-rosenthal syndrome 9.8
571 papillomatosis, confluent and reticulated 9.8
572 retinal detachment 9.8
573 testicular torsion 9.8
574 tinea imbricata 9.8
575 budd-chiari syndrome 9.8
576 pars planitis 9.8
577 anxiety 9.8
578 buruli ulcer 9.8
579 leukemia, acute lymphoblastic 9.8
580 dengue virus 9.8
581 membranous nephropathy 9.8
582 angiostrongyliasis 9.8
583 thelaziasis 9.8
584 intestinal schistosomiasis 9.8
585 sexual disorder 9.8
586 lymphoma 9.8
587 thrombosis 9.8
588 lymphocytic leukemia 9.8
589 yaws 9.8
590 protein-losing enteropathy 9.8
591 interstitial nephritis 9.8
592 paragonimiasis 9.8
593 bubonic plague 9.8
594 western equine encephalitis 9.8
595 myiasis 9.8
596 gnathomiasis 9.8
597 pulmonary edema 9.8
598 heart disease 9.8
599 cardiac tamponade 9.8
600 infant gynecomastia 9.8
601 visual epilepsy 9.8
602 pancytopenia 9.8
603 capillariasis 9.8
604 gynecomastia 9.8
605 guillain-barre syndrome 9.8
606 focal segmental glomerulosclerosis 9.8
607 endemic goiter 9.8
608 opisthorchiasis 9.8
609 iritis 9.8
610 disease of mental health 9.8
611 nodular nonsuppurative panniculitis 9.8
612 breast fibroadenoma 9.8
613 squamous cell carcinoma 9.8
614 status epilepticus 9.8
615 giant cell reparative granuloma 9.8
616 melanoma 9.8
617 hypogonadism 9.8
618 papilloma 9.8
619 adenocarcinoma 9.8
620 granulomatous orchitis 9.8
621 gallbladder cancer 9.8
622 mammary paget's disease 9.8
623 gallbladder adenocarcinoma 9.8
624 thrombophlebitis 9.8
625 syphilis 9.8
626 hypertrichosis 9.8
627 ebola hemorrhagic fever 9.8
628 pustulosis of palm and sole 9.8
629 mucoepidermoid carcinoma 9.8
630 proliferative glomerulonephritis 9.8
631 mesangial proliferative glomerulonephritis 9.8
632 ovarian cyst 9.8
633 infertility 9.8
634 paraplegia 9.8
635 b-cell lymphoma 9.8
636 hypogonadotropism 9.8
637 actinomycosis 9.8
638 vasculitis 9.8
639 dermatophytosis 9.8
640 iridocyclitis 9.8
641 tracheitis 9.8
642 intracranial hypertension 9.8
643 babesiosis 9.8
644 noma 9.8
645 tenosynovitis 9.8
646 glioma 9.8
647 gnathostoma infection 9.8
648 koro 9.8
649 prurigo nodularis 9.8
650 depression 9.8
651 seizure disorder 9.8
652 posttransplant acute limbic encephalitis 9.8
653 systemic autoimmune disease 9.8
654 glial tumor 9.8
655 argyria 9.8
656 pik3ca-related overgrowth syndrome 9.8
657 herpangina 9.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
658 conjunctivitis 9.8 TNF IL6 IL5 IL2 IL10 IGHE
659 peripheral nervous system disease 9.8 TNF TLR4 TLR2 IL6 IL2 IL10
660 connective tissue disease 9.7 TNF TLR4 TLR2 IL6 IL2 IL10
661 tonsillitis 9.7 TNF TLR9 TLR4 TLR2 TLR1 IL6
662 conjunctival disease 9.7 TNF TLR4 TLR2 IL6 IL5 IL2
663 splenic disease 9.7 TNF TLR9 TLR4 TLR2 IL6 IL2
664 food allergy 9.7 TNF TLR4 TLR2 IL5 IL10 IGHE
665 viral hepatitis 9.7 TNF TLR9 TLR4 TLR2 IL6 IL2
666 crohn's disease 9.7 TNF TLR9 TLR4 TLR2 IL6 IL2
667 myocardial infarction 9.7 TNF TLR4 TLR2 IL6 IL10 IFNG
668 testicular disease 9.7 TNF TLR4 TLR2 TLR1 IL6 IL2
669 primary biliary cirrhosis 9.7 TNF TLR9 TLR4 IL6 IL2 IL10
670 myeloma, multiple 9.7 TNF TLR9 TLR4 IL6 IL2 IL10
671 rhinitis 9.7 TNF IL6 IL5 IL10 IGHE IFNG
672 lymphatic system disease 9.7 TNF IL6 IL2 IL10 IFNG FOXC2
673 hypersensitivity reaction type iv disease 9.6 TNF TLR4 TLR2 IL6 IL2 IL10
674 upper respiratory tract disease 9.6 TNF TLR9 TLR4 TLR2 IL6 IL5
675 rectal disease 9.6 TNF TLR9 TLR6 TLR4 TLR2 TLR1
676 thrombocytopenia 9.6 TNF TLR9 TLR4 TLR2 IL6 IL2
677 cervical cancer 9.6 TNF TLR9 TLR4 IL6 IL2 IL10
678 diabetes mellitus 9.6 TNF TLR4 TLR2 IL6 IL2 IL10
679 commensal bacterial infectious disease 9.6 TNF TLR9 TLR4 TLR2 TLR1 IL6
680 gastric adenocarcinoma 9.6 TNF PDCD1LG2 IL6 IFNG FLT4
681 vaginal disease 9.5 TNF TLR9 TLR6 TLR4 TLR2 TLR1
682 rheumatoid arthritis 9.5 TNF TLR9 TLR4 TLR2 IL6 IL2
683 salmonellosis 9.5 TNF TLR9 TLR6 TLR4 TLR2 TLR1
684 otitis media 9.5 TNF TLR4 TLR2 TLR1 IL6 IL5
685 pulmonary fibrosis, idiopathic 9.5 TNF TLR9 TLR4 TLR2 IL6 IL5
686 diabetes mellitus, noninsulin-dependent 9.5 TNF TLR9 TLR6 TLR4 TLR2 TLR1
687 eye disease 9.4 TNF TLR4 TLR2 IL6 IL5 IL2
688 coccidiosis 9.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
689 meningitis 9.4 TNF TLR9 TLR4 TLR2 IL6 IL5
690 nose disease 9.4 TNF TLR9 TLR4 TLR2 IL6 IL5
691 nasal cavity disease 9.4 TNF TLR9 TLR4 TLR2 IL6 IL5
692 viral infectious disease 9.4 TNF TLR9 TLR4 TLR2 TLR1 IL6
693 bronchiolitis 9.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
694 aspergillosis 9.4 TNF TLR9 TLR6 TLR4 TLR2 TLR1
695 opportunistic mycosis 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
696 bone inflammation disease 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
697 autoimmune disease of musculoskeletal system 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
698 diabetes mellitus, insulin-dependent 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
699 behcet syndrome 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
700 body mass index quantitative trait locus 11 9.3 TNF TLR9 TLR6 TLR4 TLR2 TLR1
701 pneumonia 9.2 TNF TLR9 TLR6 TLR4 TLR2 IL6
702 autoimmune disease of central nervous system 9.2 TNF TLR9 TLR4 TLR2 TLR1 IL6
703 celiac disease 1 9.2 TNF TLR9 TLR6 TLR4 TLR2 TLR1
704 hypertension, essential 9.2 TNF TLR9 TLR6 TLR4 TLR2 TLR1
705 multiple sclerosis 9.1 TNF TLR9 TLR4 TLR2 IL6 IL5
706 bronchial disease 9.1 TNF TLR9 TLR6 TLR4 TLR2 TLR1
707 immune system disease 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
708 primary bacterial infectious disease 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
709 inflammatory bowel disease 9.0 TNF TLR9 TLR6 TLR4 TLR2 TLR1
710 colorectal cancer 8.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

45 (showing 10, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.35 ALB CCL5 CHIT1 CTLA4 FLT4 FOXC2
2 hematopoietic system MP:0005397 10.28 CCL5 CTLA4 IFNG IL10 IL2 IL5
3 homeostasis/metabolism MP:0005376 10.28 ALB CTLA4 FLT4 FOXC2 IFNG IL10
4 digestive/alimentary MP:0005381 10.27 ALB CTLA4 FLT4 FOXC2 IFNG IL10
5 cardiovascular system MP:0005385 10.22 ALB CTLA4 FLT4 FOXC2 IFNG IL10
6 liver/biliary system MP:0005370 10.1 ALB CTLA4 FLT4 FOXC2 IFNG IL10
7 muscle MP:0005369 9.91 ALB FLT4 FOXC2 IFNG IL10 IL6
8 neoplasm MP:0002006 9.85 ALB IFNG IL10 IL2 IL5 IL6
9 no phenotypic analysis MP:0003012 9.5 FLT4 FOXC2 IFNG IL10 IL2 PDCD1LG2
10 respiratory system MP:0005388 9.32 CTLA4 FOXC2 IFNG IL10 IL2 IL5

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 33, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3 Anti-Bacterial Agents Phase 4
4 Antimalarials Phase 4
5 Vitamins Phase 3
6 Reslizumab Approved, Investigational Phase 2
7
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
8
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
9 Artemisinins Phase 2
10 Artemisinine Phase 2
11 Antibodies, Monoclonal Phase 2
12 Respiratory System Agents Phase 2
13 Anti-Asthmatic Agents Phase 2
14 Immunoglobulins Phase 2
15 Antibodies Phase 2
16 Imatinib Mesylate Phase 2 220127-57-1 123596
17 Protein Kinase Inhibitors Phase 2
18
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
19
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
20 Pharmaceutical Solutions Phase 1
21
Polidocanol Approved 9002-92-0
22
Piperazine Approved, Vet_approved 110-85-0 4837
23
Mebendazole Approved, Vet_approved 31431-39-7 4030
24
Sodium citrate Approved, Investigational 68-04-2
25
Permethrin Approved, Investigational 52645-53-1 40326
26
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
27 Anesthetics
28 Sclerosing Solutions
29 Piperazine citrate
30 Citrate
31 DMP 777 157341-41-8
32 Liver Extracts
33 Insect Repellents

Interventional clinical trials:

(showing 58, show less)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
3 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
4 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
11 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
12 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
15 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
16 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
17 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
20 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
21 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
22 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
23 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
24 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Recruiting NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
25 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
26 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
27 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
28 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
29 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
30 Exhaled NO Testing in Filariasis Completed NCT01628497
31 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
32 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
33 Research for Elimination of Human Filariasis Completed NCT00145223
34 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
35 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
36 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
37 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
38 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
39 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
40 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
42 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
43 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
44 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
45 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
46 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
47 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
48 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
49 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
50 Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis Completed NCT00001245
51 Veron Scabies Education and Eradication Program Completed NCT00604084 Ivermectin;Permethrin 5% lotion
52 Comparison Trial Between Two Repellent Products and a Positive Control Against Culicoides Nubeculosus Midges Completed NCT04028180
53 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Recruiting NCT03352206 2 drug dose - DA;3 drug dose - IDA
54 Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis Recruiting NCT01547884
55 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Recruiting NCT03683745
56 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
57 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
58 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;Albendazole 400mg and ivermectin 200mcg/kg;albendazole 800mg and ivermectin 400mcg/kg bi-annually

Search NIH Clinical Center for Filariasis

Cochrane evidence based reviews: filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

40
Testes, T Cells, Breast, Skin, Lung, Liver, B Cells

Publications for Filariasis

Articles related to Filariasis:

(showing 6318, show less)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 54 61
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 54 61
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 54 61
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 54 61
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 54 61
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 54 61
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 54 61
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 54 61
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 54 61
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 54 61
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 54 61
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 54 61
2112154 1990
13
Advances in Vaccine Development for Human Lymphatic Filariasis. 61
31864894 2020
14
Massive microfilaremia in a dog subclinically infected with Acanthocheilonema dracunculoides. 61
32036036 2020
15
Activation of mosquito immunity blocks the development of transmission-stage filarial nematodes. 61
32015105 2020
16
Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. 61
31678122 2020
17
The genome of Setaria digitata, a cattle nematode closely related to human filarial parasites. 61
32022853 2020
18
The rise or fall of neglected tropical diseases in East Asia Pacific. 61
31550453 2020
19
Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. 61
31840757 2020
20
Filariasis with Squamous Cell Carcinoma: A Hidden Surprise. 61
32002388 2020
21
Genital filariasis presenting as a vaginal wall cystic lesion. 61
31768314 2020
22
Cutaneous Filariasis in Free-Ranging Rothschild's Giraffes (Giraffa camelopardalis rothschildi) in Uganda. 61
31532733 2020
23
Loa loa filariasis in a tropical savanna area: report of one case in Ouagadougou. 61
31975376 2020
24
A review on the druggability of a thiol-based enzymatic antioxidant thioredoxin reductase for treating filariasis and other parasitic infections. 61
31521661 2020
25
Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India. 61
31978060 2020
26
Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India. 61
31769393 2020
27
Brugia malayi galectin 2 is a tandem-repeat type galectin capable of binding mammalian polysaccharides. 61
31738955 2020
28
In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. 61
31986143 2020
29
Isolated Epitrochlear Filarial Lymphadenopathy: Cytomorphological Diagnosis of an Unusual Presentation. 61
29630086 2020
30
Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. 61
31930383 2020
31
Antifilarial effect of nanocomposite of silver nanoparticles with nitazoxanide against the microfilariae of Setaria cervi-infected albino rats. 61
32002575 2020
32
Integrated Cross-Sectional Multiplex Serosurveillance of IgG Antibody Responses to Parasitic Diseases and Vaccines in Coastal Kenya. 61
31769388 2020
33
High Circulation of Malaria and Low Prevalence of Bacteremia in Febrile and Afebrile Children in Northeastern Gabon. 61
31769404 2020
34
Safety of high-dose ivermectin: a systematic review and meta-analysis. 61
31960060 2020
35
Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration. 61
31941448 2020
36
From parasitic disease control to global health: New orientation of the National Institute of Parasitic Diseases, China CDC. 61
31614120 2020
37
Testing a method of sampling for entomological determination of transmission of Wuchereria bancrofti to inform lymphatic filariasis treatment strategy in urban settings. 61
31973747 2020
38
Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. 61
31876154 2020
39
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. 61
31948767 2020
40
Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. 61
32007449 2020
41
Role of Bone Marrow Examination in the Evaluation of Infections: Clinico-Hematological Analysis in a Tertiary Care Centre. 61
31522489 2020
42
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold. 61
31853554 2019
43
An insight into the discovery of potent antifilarial leads against lymphatic filariasis. 61
31800381 2019
44
Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. 61
31655132 2019
45
Canine Brugia malayi microfilarial excretory/secretory protein-based antibody assay for the diagnosis of brugian filariasis in dogs. 61
31749523 2019
46
Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics. 61
31796568 2019
47
An Expanded Transmission Assessment Survey to Confirm the Interruption of Lymphatic Filariasis Transmission in Wallis and Futuna. 61
31595868 2019
48
Surgical Treatment of Advanced Lymphatic Filariasis of Lower Extremity Combining Vascularized Lymph Node Transfer and Excisional Procedures. 61
31038386 2019
49
The consequences of Brugia malayi infection on the flight and energy resources of Aedes aegypti mosquitoes. 61
31804546 2019
50
De novo Assembly of the Brugia malayi Genome Using Long Reads from a Single MinION Flowcell. 61
31863009 2019
51
Evaluation of Pistia stratiotes fractions as effective larvicide against Anopheles mosquitoes. 61
30855191 2019
52
Intra-Rater Reliability and Agreement of the Indurometer When Used to Assess Mid-Calf Tissue Compressibility Among People Affected by Moderate to Severe Lymphedema in Bangladesh and Ethiopia. 61
31859599 2019
53
Gender-related factors affecting health seeking for neglected tropical diseases: findings from a qualitative study in Ethiopia. 61
31830026 2019
54
Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. 61
31400299 2019
55
Assessment of transmission in areas of uncertain endemicity for lymphatic filariasis in Brazil. 61
31765388 2019
56
A Mathematical Model for the Transmission Dynamics of Lymphatic Filariasis with Intervention Strategies. 61
31758278 2019
57
Evaluating the Evidence for Lymphatic Filariasis Elimination. 61
31506245 2019
58
How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia. 61
31774820 2019
59
Study on vector mosquito of zoonotic Brugia malayi in Musi Rawas, South Sumatera, Indonesia. 61
32009751 2019
60
Bioengineering of Piper longum L. extract mediated silver nanoparticles and their potential biomedical applications. 61
31500006 2019
61
Current status of neglected tropical diseases (NTDs) in the Philippines. 61
31786109 2019
62
Diagnosis of filariasis by cytology of unexplained ascites. 61
31254318 2019
63
Portable infrared imaging for longitudinal limb volume monitoring in patients with lymphatic filariasis. 61
31584959 2019
64
Molecular evolution of single chain fragment variable (scFv) for diagnosis of lymphatic filariasis. 61
31512046 2019
65
Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Côte d'Ivoire: an open-label, randomized, controlled trial. 61
31641754 2019
66
IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism. 61
31485865 2019
67
Microfilaria and Strongyloides larva diagnosed in cerebrospinal fluid and ascitic fluid, respectively: Approach to their morphology on cytology. 61
31211515 2019
68
Parasitic chyluria in a 72-year-old Sierra Leonean woman: A case report. 61
31714130 2019
69
Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions. 61
31578157 2019
70
Rare association of microfilaria with poorly differentiated mucin-secreting metastatic carcinoma in liver aspirate cytology. 61
31645405 2019
71
Neglected tropical diseases in the People's Republic of China: progress towards elimination. 61
31578147 2019
72
Whatever happened to China's neglected tropical diseases? 61
31578156 2019
73
Comparison of Staging Systems to Assess Lymphedema Caused by Cancer Therapies, Lymphatic Filariasis, and Podoconiosis. 61
30789319 2019
74
Applications of machine learning techniques to predict filariasis using socio-economic factors. 61
31475670 2019
75
Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis. 61
31513587 2019
76
Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. 61
31557154 2019
77
Mapping the baseline prevalence of lymphatic filariasis across Nigeria. 61
31522689 2019
78
Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study. 61
31681683 2019
79
Coumarin (2H-1-benzopyran-2-one): a novel and eco-friendly aphicide. 61
31507220 2019
80
Morphological and genetic variation of Wuchereria bancrofti microfilariae in carriers in Thailand, Lao PDR and Myanmar: evaluation using Giemsa-stained thick blood films. 61
31564254 2019
81
Human Migration and the Spread of the Nematode Parasite Wuchereria bancrofti. 61
31077328 2019
82
Rare cause of floaters: A motile live worm in vitreous cavity. 61
31436210 2019
83
Antifilarial activity of azadirachtin fuelled through reactive oxygen species induced apoptosis: a thorough molecular study on Setaria cervi. 61
30032733 2019
84
The division of labour between community medicine distributors influences the reach of mass drug administration: A cross-sectional study in rural Uganda. 61
31483784 2019
85
Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic. 61
31340171 2019
86
An Enhanced Self-Care Protocol for People Affected by Moderate to Severe Lymphedema. 61
31487887 2019
87
Pyruvate produced by Brugia spp. via glycolysis is essential for maintaining the mutualistic association between the parasite and its endosymbiont, Wolbachia. 61
31568486 2019
88
Parasitic infections in Malaysian aborigines with pulmonary tuberculosis: a comparative cross-sectional study. 61
31363922 2019
89
Neglected tropical disease as a 'biographical disruption': Listening to the narratives of affected persons to develop integrated people centred care in Liberia. 61
31490931 2019
90
BioStruct-Africa: empowering Africa-based scientists through structural biology knowledge transfer and mentoring - recent advances and future perspectives. 61
31490179 2019
91
Emodepside has sex-dependent immobilizing effects on adult Brugia malayi due to a differentially spliced binding pocket in the RCK1 region of the SLO-1 K channel. 61
31553770 2019
92
EBM verdict: should albendazole be used for treating lymphatic filariasis? No. 61
30971416 2019
93
Development of an Antigen Detection ELISA for Bancroftian Filariasis Using BmSXP-Specific Recombinant Monoclonal Antibody. 61
31162018 2019
94
Correction to: How Thailand eliminated lymphatic filariasis as a public health problem. 61
31420004 2019
95
Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China. 61
31387644 2019
96
Transcriptomic analysis of insecticide resistance in the lymphatic filariasis vector Culex quinquefasciatus. 61
31388075 2019
97
Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities. 61
31398203 2019
98
Immune Response to Brugia malayi Asparaginyl-tRNA Synthetase in Balb/c Mice and Human Clinical Samples of Lymphatic Filariasis. 61
30570354 2019
99
IL-4 receptor dependent expansion of lung CD169+ macrophages in microfilaria-driven inflammation. 61
31469835 2019
100
Ivermectin: From theory to clinical application. 61
31071469 2019
101
Identification and classification of differentially expressed genes in pyrethroid-resistant Culex pipiens pallens. 61
30904950 2019
102
Current Status of Parasite Infections in Indonesia: A Literature Review. 61
31533400 2019
103
Novel odor-based strategies for integrated management of vectors of disease. 61
31247410 2019
104
Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells. 61
31425508 2019
105
Evaluation of an ultraviolet LED trap for catching Anopheles and Culex mosquitoes in south-eastern Tanzania. 61
31455370 2019
106
The Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 61
31402376 2019
107
Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach. 61
31314753 2019
108
Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis. 61
31276494 2019
109
Ecological and Socioeconomic Predictors of Transmission Assessment Survey Failure for Lymphatic Filariasis. 61
31115301 2019
110
Lymphatic filariasis presenting as a soft tissue swelling in midarm: A histopathological diagnosis at unusual site. 61
31579668 2019
111
Eliminating lymphatic filariasis - Is it worth it? 61
31343066 2019
112
Filariasis presenting as a solitary testicular mass. 61
31579667 2019
113
The health and economic burden of lymphatic filariasis prior to mass drug administration programmes. 61
31343064 2019
114
Self-reactive IgG4 antibodies are associated with blocking of pathology in human lymphatic filariasis. 61
31130239 2019
115
Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis. 61
31260444 2019
116
Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals. 61
31306409 2019
117
Microfilaria: not always associated with eosinophilia. 61
30895888 2019
118
Potential of hydrocarbon and oxygenated monoterpenes against Culex pipiens larvae: Toxicity, biochemical, pharmacophore modeling and molecular docking studies. 61
31378352 2019
119
Molecular Analysis of Canine Filaria and Its Wolbachia Endosymbionts in Domestic Dogs Collected from Two Animal University Hospitals in Bangkok Metropolitan Region, Thailand. 61
31362350 2019
120
Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions. 61
31262367 2019
121
Microfilaria Infection in Metastatic Node in a Case of Breast Carcinoma. 61
31579198 2019
122
Travelers' tropical skin diseases: Challenges and interventions. 61
30216601 2019
123
Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. 61
29969926 2019
124
Toll-like receptor polymorphism in host immune response to infectious diseases: A review. 61
31054156 2019
125
Utility of cytology in the diagnosis of parasitic infestation: A retrospective study. 61
31579663 2019
126
Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives. 61
31496523 2019
127
Diagnosis of tubo-ovarian filariasis with retroperitoneal extension: A radiological challenge. 61
31334196 2019
128
GEOFIL: A spatially-explicit agent-based modelling framework for predicting the long-term transmission dynamics of lymphatic filariasis in American Samoa. 61
30611745 2019
129
Bridging the gap in outreach and compliance with mass drug administration for lymphatic filariasis elimination in an endemic district in Kerala, India: an intervention research approach. 61
30805648 2019
130
The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. 61
31233507 2019
131
A detailed review of the mosquitoes (Diptera: Culicidae) of Iran and their medical and veterinary importance. 61
30898616 2019
132
Discovery of Kirromycins with Anti- Wolbachia Activity from Streptomyces sp. CB00686. 61
31074963 2019
133
Development of a High-Throughput Cytometric Screen to Identify Anti- Wolbachia Compounds: The Power of Public-Private Partnership. 61
30958712 2019
134
New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. 61
30947125 2019
135
Troponin 1 of human filarial parasite Brugia malayi: cDNA cloning, expression, purification, and its immunoprophylactic potential. 61
31055672 2019
136
Using Ecological Niche Modeling to Predict the Spatial Distribution of Anopheles maculipennis s.l. and Culex theileri (Diptera: Culicidae) in Central Iran. 61
31803777 2019
137
Lymphatic Filariasis. 61
31027660 2019
138
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. 61
29860672 2019
139
Neglected Tropical Diseases: The Potential Application to Monitoring by microRNAs in the Real World. 61
31218967 2019
140
How Thailand eliminated lymphatic filariasis as a public health problem. 61
31130143 2019
141
[Technique for extracting ocular filariasis]. 61
30981543 2019
142
Evaluation of lymphatic filariasis in endemic area of Brazil where mass drug administration is not required. 61
31138026 2019
143
Assessment of treatment impact on lymphatic filariasis in 13 districts of Benin: progress toward elimination in nine districts despite persistence of transmission in some areas. 61
31146779 2019
144
The use of variable temperature 13 C solid-state MAS NMR and GIPAW DFT calculations to explore the dynamics of diethylcarbamazine citrate. 61
30114322 2019
145
Wuchereria bancrofti filaria activates human dendritic cells and polarizes T helper 1 and regulatory T cells via toll-like receptor 4. 61
31924989 2019
146
[ISRAELI VOLUNTEERS ON THE YWAM SHIP, PAPUA NEW GUINEA, 2018]. 61
31104391 2019
147
Wuchereria bancrofti-infected individuals harbor distinct IL-10-producing regulatory B and T cell subsets which are affected by anti-filarial treatment. 61
31120872 2019
148
Influence of seasonal variation on reported filarial attacks among people living with lymphedema in Ghana. 61
31109288 2019
149
A multiplex PCR assay for the identification of five species of the Anopheles barbirostris complex in Thailand. 61
31088534 2019
150
Development and application of a tri-allelic PCR assay for screening Vgsc-L1014F kdr mutations associated with pyrethroid and organochlorine resistance in the mosquito Culex quinquefasciatus. 61
31088572 2019
151
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. 61
31107869 2019
152
Genomic analyses of aminoacyl tRNA synthetases from human-infecting helminths. 61
31046663 2019
153
Prevalence of malaria and lymphatic filariasis in bateyes of the Dominican Republic. 61
31130142 2019
154
Geographical distribution and prevalence of podoconiosis in Rwanda: a cross-sectional country-wide survey. 61
30926303 2019
155
Preventive chemotherapy reverses covert, lymphatic-associated tissue change in young people with lymphatic filariasis in Myanmar. 61
30706585 2019
156
Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo. 61
30971305 2019
157
Diagnosis of feline filariasis assisted by a novel semi-automated microfluidic device in combination with high resolution melting real-time PCR. 61
30961652 2019
158
Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka. 61
31009482 2019
159
Culex species diversity, susceptibility to insecticides and role as potential vector of Lymphatic filariasis in the city of Yaoundé, Cameroon. 61
30943198 2019
160
Complete Genome Sequence of the Corallopyronin A-Producing Myxobacterium Corallococcus coralloides B035. 61
31023790 2019
161
Immunomodulatory Activity of Sulfonamide Chalcone Compounds in Mice Infected with Filarial Parasite, Brugia malayi. 61
31092998 2019
162
Cytochrome P450 Mono-Oxygenase and Resistance Phenotype in DDT and Deltamethrin-Resistant Anopheles gambiae (Diptera: Culicidae) and Culex quinquefasciatus in Kosofe, Lagos, Nigeria. 61
30753574 2019
163
First study of topical selamectin efficacy for treating cats naturally infected with Brugia malayi and Brugia pahangi under field conditions. 61
30746583 2019
164
The social, physical and economic impact of lymphedema and hydrocele: a matched cross-sectional study in rural Nigeria. 61
31014256 2019
165
The Concept of Chronic Edema-A Neglected Public Health Issue and an International Response: The LIMPRINT Study. 61
30995179 2019
166
Trends in insecticide resistance in Culex pipiens pallens over 20 years in Shandong, China. 61
30975185 2019
167
Residual Efficacy of Insecticides Sprayed on Different Types of Surfaces Against Leishmaniasis and Filariasis Vectors in Egypt. 61
30753681 2019
168
Inflammatory and regulatory CCL and CXCL chemokine and cytokine cellular responses in patients with patent Mansonella perstans filariasis. 61
30561772 2019
169
How lymphatic filariasis was eliminated from an urban poor setting in Santo Domingo, Dominican Republic. 61
30285112 2019
170
Review of Dancing Parasites in Lymphatic Filariasis. 61
31312785 2019
171
Investigation of Mixture Modelling Algorithms as a Tool for Determining the Statistical Likelihood of Serological Exposure to Filariasis Utilizing Historical Data from the Lymphatic Filariasis Surveillance Program in Vanuatu. 61
30857178 2019
172
Epidemiological screening and xenomonitoring for human lymphatic filariasis infection in select districts in the states of Maharashtra and Karnataka, India. 61
30666407 2019
173
Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. 61
30867321 2019
174
Using intervention mapping to design and implement quality improvement strategies towards elimination of lymphatic filariasis in Northern Ghana. 61
30908495 2019
175
Assessing the Presence of Wuchereria bancrofti Infections in Vectors Using Xenomonitoring in Lymphatic Filariasis Endemic Districts in Ghana. 61
30884886 2019
176
Mapping of lymphatic filariasis in loiasis areas: A new strategy shows no evidence for Wuchereria bancrofti endemicity in Cameroon. 61
30849120 2019
177
The Genetic Polymorphisms of 24 Base Pair Duplication and Point G102S of Human Chitotriosidase to Bancroftian Filariasis at the Thai⁻Myanmar Border. 61
30934653 2019
178
The Wolbachia Endosymbionts. 61
30953430 2019
179
Detection of Mansonella ozzardi among blood donors from highly endemic interior cities of Amazonas state, northern Brazil. 61
30566229 2019
180
Exploring the Insecticidal Potential of Boldo (Peumus boldus) Essential Oil: Toxicity to Pests and Vectors and Non-target Impact on the Microcrustacean Daphnia magna. 61
30832296 2019
181
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. 61
30730745 2019
182
The Global Burden of Disease of Zoonotic Parasitic Diseases: Top 5 Contenders for Priority Consideration. 61
30832380 2019
183
Profiling the best-performing community medicine distributors for mass drug administration: a comprehensive, data-driven analysis of treatment for schistosomiasis, lymphatic filariasis, and soil-transmitted helminths in Uganda. 61
30917824 2019
184
Decreased nematode clearance and anti-phosphorylcholine-specific IgM responses in mannose-binding lectin-deficient mice. 61
30457677 2019
185
Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort. 61
30594267 2019
186
A surveillance system for lymphatic filariasis after its elimination in Sri Lanka. 61
30308253 2019
187
Non-compliance to mass drug administration associated with the low perception of the community members about their susceptibility to lymphatic filariasis in Ankobra, Ghana. 61
30727921 2019
188
Evaluation of the effect of mass drug administration against lymphatic filariasis in three health districts and public health implications: study of 12 epidemiological surveillance sites in Burkina Faso. 61
31031248 2019
189
Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia. 61
30560772 2019
190
Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors. 61
30717788 2019
191
Effect of Serratia AS1 (Enterobacteriaceae: Enterobacteriales) on the Fitness of Culex pipiens (Diptera: Culicidae) for Paratransgenic and RNAi Approaches. 61
30388221 2019
192
Environmental factors associated with the distribution of Loa loa vectors Chrysops spp. in Central and West Africa: seeing the forest for the trees. 61
30728063 2019
193
Immunological evaluation of fusion protein of Brugia malayi abundant larval protein transcript-2 (BmALT-2) and Tuftsin in experimental mice model. 61
30847408 2019
194
Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity. 61
30818326 2019
195
The central adaptor molecule TRIF influences L. sigmodontis worm development. 61
30643971 2019
196
Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches. 61
29334340 2019
197
Comparative analysis of excretory-secretory antigens of Anisakis simplex, Pseudoterranova decipiens and Contracaecum osculatum regarding their applicability for specific serodiagnosis of human anisakidosis based on IgG-ELISA. 61
30584924 2019
198
Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease. 61
30614200 2019
199
AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis. 61
30617067 2019
200
Fine-needle aspiration of axillary swelling: Cytodiagnosis of an unusual presentation of filariasis. 61
31897083 2019
201
Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. 61
30620051 2019
202
Elimination of lymphatic filariasis as a public health problem in Niue under PacELF, 1999-2016. 61
30923457 2019
203
The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling. 61
31728440 2019
204
Burden of hydrocoele assessed from medical and surgical records in a lymphatic filariasis endemic country, Samoa. 61
31719790 2019
205
Filariasis: a vasculitis mimic. 61
31858075 2019
206
Epididymal filariasis a rare presentation of testicular pain. 61
30306047 2019
207
Recent Advances in Medicinal Chemistry to Treat Filariasis and Helminthiasis. 61
31509098 2019
208
Elimination of lymphatic filariasis in South East Asia. 61
30670373 2019
209
Ocular filariasis: "Dancing sensation in the anterior chamber". 61
31161094 2019
210
Elimination of lymphatic filariasis as a public health problem from Tonga. 61
31346312 2019
211
Mapping and monitoring for a lymphatic filariasis elimination program: a systematic review. 61
31239804 2019
212
Are census data accurate for estimating coverage of a lymphatic filariasis MDA campaign? Results of a survey in Sierra Leone. 61
31856176 2019
213
Insecticide resistance mapping in the vector of lymphatic filariasis, Culex quinquefasciatus Say from northern region of West Bengal, India. 61
31141548 2019
214
Quantifying the Influence of Larval Density on Disease Transmission Indices in Culex quinquefasciatus, the Major African Vector of Filariasis. 61
31258336 2019
215
Community and Drug Distributor Perceptions and Experiences of Mass Drug Administration for the Elimination of Lymphatic Filariasis: A Rapid Review of Qualitative Research. 61
30878056 2019
216
Insecticidal efficacy of the essential oil of jambú (Acmella oleracea (L.) R.K. Jansen) cultivated in central Italy against filariasis mosquito vectors, houseflies and moth pests. 61
30149065 2019
217
Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana. 61
30608931 2019
218
Giant filarial retroperitoneal cyst: a diagnostic dilemma. 61
31223269 2019
219
Wuchereria bancrofti filaria activates human dendritic cells and polarizes T helper 1 and regulatory T cells via toll-like receptor 4. 61
31098402 2019
220
Immunodiagnostic potential of Wuchereria bancrofti L1 antigen-based filarial immunoglobulin G4 detection assay. 61
30321407 2019
221
Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. 61
30602718 2019
222
Immunogenicity and protective efficacy of Recombinase A from Wolbachia endosymbiont of filarial nematode Brugia malayi (wBmRecA). 61
30595344 2019
223
Surveillance of Wuchereria bancrofti infection by anti-filarial IgG4 in urine among schoolchildren and molecular xenomonitoring in Sri Lanka: a post mass drug administration study. 61
31223271 2019
224
Therapeutic Potential of Citronella Essential Oil: A Review. 61
30019646 2019
225
Larvicidal Activity of Synthesized Silver Nanoparticles from Curcuma zedoaria Essential Oil against Culex quinquefasciatus. 61
30641859 2019
226
Genetic association of MBL-2 gene polymorphisms with Filarial chyluria. 61
31902980 2019
227
Strategies to Control Human Lymphatic Filarial Infection: Tweaking Host's Immune System. 61
31244425 2019
228
In Vitro and In Silico Studies of Glycyrrhetinic Acid Derivatives as Anti- Filarial Agents. 61
31210109 2019
229
Immunochemical Characterization of Setaria cervi Microfilarial Antigens Using Novel Antibodies. 61
31244426 2019
230
Prevalence, Intensity of Soil-Transmitted Helminths, and Factors Associated with Infection: Importance in Control Program with Ivermectin and Albendazole in Eastern Côte d'Ivoire. 61
31019535 2019
231
Supervision and support in surgical practice using mobile platform: a case of mass hydrocele surgeries in remote regions. 61
31620468 2019
232
In Vitro and In Vivo Antifilarial Activity of Standardized Extract of Calotropis procera Flowers against Brugia malayi. 61
31218959 2019
233
Evaluation of the inhibitory effect of ivermectin on the growth of Babesia and Theileria parasites in vitro and in vivo. 61
31337949 2019
234
Effect of flubendazole on developing stages of Loa loa in vitro and in vivo: a new approach for screening filaricidal agents. 61
30621774 2019
235
Multi-disciplinary integration of networking through the RNAS+: Research on other target diseases. 61
31530397 2019
236
Entomological assessment of the transmission following recrudescence of onchocerciasis in the Comoé Valley, Burkina Faso. 61
30646934 2019
237
Genomic Epidemiology in Filarial Nematodes: Transforming the Basis for Elimination Program Decisions. 61
31998356 2019
238
From country control programmes to translational research. 61
31530396 2019
239
Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test. 61
30699120 2019
240
Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi. 61
30650084 2019
241
New strains of Japanese encephalitis virus circulating in Shanghai, China after a ten-year hiatus in local mosquito surveillance. 61
30626442 2019
242
No evidence of Zika, dengue, or chikungunya virus infection in field-caught mosquitoes from the Recife Metropolitan Region, Brazil, 2015. 61
31363498 2019
243
Penile and scrotal lymphedema associated with hidradenitis suppurativa: Case report and review of surgical options. 61
30951036 2019
244
Laboratory Evaluation of a Rapid IgG4 Antibody Test (BLF Rapid™) for Bancroftian Filariasis. 61
30350768 2018
245
Larvicidal activity of some medicinal plant extracts against filariasis fever mosquito, Culex quinquefasciatus (Say.) (Diptera: Culicidae). 61
30502827 2018
246
Implementing a community vector collection strategy using xenomonitoring for the endgame of lymphatic filariasis elimination. 61
30587226 2018
247
Chicory (Cichorium intybus) and wormwood (Artemisia absinthium) extracts exhibit strong larvicidal activity against mosquito vectors of malaria, dengue fever, and filariasis. 61
30118862 2018
248
The Effect of a Regimen of Antifungal Cream Use on Episodes of Acute Adenolymphangitis (ADL) among Lymphedema Patients: An Application Using Marginal Structural Models. 61
30864760 2018
249
Kernel-density estimation and approximate Bayesian computation for flexible epidemiological model fitting in Python. 61